Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The International Court of Arbitration, International Chamber of Commerce (ICC), has issued its arbitral award in the arbitration filed by R-Tech Ueno, together with Sucampo Pharmaceuticals and Sucampo, against Takeda Pharmaceutical Company.
Subscribe to our email newsletter
While not accepting the claims of R-Tech Ueno, the arbitral award said the supply agreement among R-Tech Ueno, Takeda and Sucampo executed in 2004 regarding the exclusive supply of Amitiza capsules shall continue to be in effect.
The arbitration requires R-Tech Ueno to continue supply Amitiza capsules to Takeda based on the supply agreement.
R-Tech Ueno will announce its business forecast for the fiscal year ending March 2013 after consideration of the arbitration result.
R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs, Sucampo Pharmaceuticals is a company focused on the discovery and development of proprietary drugs based on prostones.